演題詳細

ポスター / Poster

ポスター 32 (Poster 32) :悪性リンパ腫:治療

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
磯部 泰司 (Yasushi Isobe):1
1:聖マリアンナ医科大学 血液・腫瘍内科
 
前へ戻る

Clinical outcome of Primary central nervous system lymphoma: A single institute experience

演題番号 : PS-1-244

渡壁 恭子 (Kyoko Watakabe):1、加藤 実穂 (Miho Kato):1、加賀谷 裕介 (Yusuke Kagaya):1、鴨下 園子 (Sonoko Kamoshita):1、川島 直実 (Naomi Kawashima):1、横畠 絵美 (Emi Yokohata):1、金光 奈緒子 (Naoko Kanemitsu):1、倉橋 信悟 (Shingo Kurahashi):1、小澤 幸泰 (Yukiyasu Ozawa):1、宮村 耕一 (Koichi Miyamura):1

1:Depertment of Hematology, Japanese Red Cross Nagoya First Hospital

 

Introduction: Primary central nervous system lymphoma (PCNSL) is unfavorable type of malignant lymphoma, and its standard therapy is not established. Although high dose methotrexate based chemotherapy (HD-MTX) and whole-brain irradiation (WBRT) improved the outcome of PCNSL, long term prognosis is not enough. In this study, we retrospectively analyzed the clinical features of PCNSL in a single institution. Patients and methods: Until Dec.2012, 17 patients with PCNSL were newly diagnosed. Eleven males and 6 females, median age 65.2 years-old (range 39-80).Three patients were treated by MTX monotherapy, 12 patients underwent HD-MTX with WBRT, 2 patients were treated by other therapy. Result: Five cases reached to complete remission (29.4%), 9 partial remission (52.9%), and 3 progressive disease (17.6%).Two PD cases were received salvage therapy, and 1 case reached to PR. In overall population, median follow up of 470 days, the overall survival was 39.2 months; a one-year OS and progression-free survival were 47.1 and 17.6% respectively. Seven of 17(41.2%) patients relapsed. In patients, older than 60 years, the overall survival was 33.8 months, and there was no difference with or without WBRT. Severe delayed neurotoxicity was shown in 72.3% among elderly patients who received WBRT, and was shown in the patient without radiation.(p= 0.006) Conclusion: It is important to discuss another treatment strategy, such as more intensive chemotherapy without radiation regimen, especially in elderly patients.

前へ戻る